AstraZeneca’s Lokelma shows significant effect in ESRD trial

The Dialize trial has evaluated the efficacy and safety of Lokelma to treat hyperkalaemia, which is a serious condition indicated by elevated potassium levels in the blood. According The post AstraZeneca’s Lokelma shows significant effect in ESRD trial appeared first on Pharmaceutical Business review.

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

The program is intended to assist drug supply chain stakeholders, including FDA, in developing the electronic, interoperable system that will identify and trace certain prescription drugs as they The post IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity appeared first on Pharmaceutical Business review.

Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). The post Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab appeared first on Pharmaceutical Business review.

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal The post FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti appeared first on Pharmaceutical Business review.

Pfizer announces results from XELJANZ XR ORAL Shift study

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were The post Pfizer announces results from XELJANZ XR ORAL Shift study appeared first on Pharmaceutical Business review.

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

PhoreMost has identified and validated the target using its next-generation SITESEEKER phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors The post Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target appeared first on Pharmaceutical Business review.

Dassault Systèmes to buy Medidata Solutions for £4.5bn

The acquisition of Medidata will help Dassault to create its first end-to-end scientific and business platform for life sciences industry. As per terms of the deal, Dassault will The post Dassault Systèmes to buy Medidata Solutions for £4.5bn appeared first on Pharmaceutical Business review.

FDA extends approval of Merck’s Keytruda in head and neck cancer

The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment The post FDA extends approval of Merck’s Keytruda in head and neck cancer appeared first on Pharmaceutical Business review.

Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

This brings together the expertise of Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras (PROTACs), based in the School of Life Sciences The post Boehringer Ingelheim, University of Dundee extend anti-cancer alliance appeared first on Pharmaceutical Business review.

Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

Cosentyx is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis The post Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study appeared first on Pharmaceutical Business review.